NCT03799913View on ClinicalTrials.gov

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

October 31, 2021

Study Completion Date

April 30, 2022

Conditions
Ovarian Cancer
Interventions
BIOLOGICAL

anti-MESO CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-MESO CARs

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

300mg/m2/d

Trial Locations (1)

310009

RECRUITING

The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

Hrain Biotechnology Co., Ltd.

INDUSTRY

lead

Zhejiang University

OTHER